This positions ER-β/GPER1 agonism as a viable intervention not only for BD, but also for schizophrenia, PTSD, and neurodegenerative conditions—particularly within male subgroups marked by chronic inflammation or monoaminergic instability. This evidence concerns the gene ESR2 and schizophrenia.